The majority (81%) found that that combination 5-FU–Cal was more effective than 5-FU monotherapy and, despite 47% reporting worse LSRs, most would prefer to use the 5-FU–Cal combination in the future. 5-FU monotherapy. This is the first evaluation of patient perspectives on the use of combination 5-FU–Cal in immunocompromised patients. Overall, 28 of 32 (87%) preferred combination 5-FU–Cal vs. 5-FU monotherapy was reported as shorter in 17 of 32 (53%), equivalent in nine of 32 (28%) and longer in four of 32 (12%).
5-FU monotherapy were reported as more severe in 15 of 32 (47%), equivalent in eight of 32 (25%) and less severe in seven of 32 (22%). Most patients ( n = 26/32 81%) reported that combination 5-FU–Cal was more effective than 5-FU monotherapy. All had previously used 5-FU and 31 of 32 (97%) had received at least one other intervention for AK (cryotherapy, n = 28 surgery, n = 18 5-FU/salicylic acid cutaneous solution, n = 11 imiquimod, n = 6 ingenol mebutate, n = 3 diclofenac gel, n = 2 photodynamic therapy, n = 4). Twenty-seven (84%) had a history of skin cancer. This included organ transplant recipients ( n = 28) patients with chronic lymphocytic leukaemia ( n = 3) and one patient with Crohn disease on azathioprine ( n = 1). 5-FU monotherapy in terms of convenience of use, effectiveness, severity and duration of local skin reactions (LSRs) and preferences for AK treatment. A total of 32 immunosuppressed patients were surveyed (25 men and seven women mean age 66 years). Patients were asked about experience with combination 5-FU–Cal vs. We administered a clinician-delivered, structured questionnaire, which included details of previous therapy for AK and skin cancer history. Immunosuppressed patients attending specialist dermatology clinics who had received combination 5-FU-Cal over the past 12 months for treatment of AK and had previously been treated with at least one course of 5-FU monotherapy were identified in three specialist centres. We surveyed immunosuppressed patients’ experiences of using both 5-FU monotherapy and combination 5-FU–Cal to evaluate their perspectives on real-world use of both topical AK treatments. However, 5-FU cream and calcipotriol ointment (5-FU–Cal) combination therapy for 4–6 days may be more effective, although the original randomized controlled trials (2017/2019) excluded immunosuppressed patients. The current standard of care is 5-fluorouracil 5% cream (5-FU) monotherapy for 4 weeks. Matin, 3 Charlotte Proby 2 and Catherine Harwood 1ġ Department of Dermatology, Royal London Hospital, London, UK 2 Department of Dermatology, Ninewells Hospital, Dundee, UK and 3 Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKĪctinic keratoses (AK) are a common problem in immunocompromised patients and are associated with an increased risk of cutaneous squamous cell carcinoma (cSCC). Muhammad Hyder Junejo, 1 Sibel Demirel, 2 Rubeta N.